|
|
2023's Stock Market Performance
|
|
2023's Stock Market Performance
|
2023's Large Cap Stocks Performance
Here are the best and worst performing Large-Cap Stocks of 2023.
The Large-Cap Company is defined with the market capitalization, trading above 5 billion dollars U.S. as of 10/03/26.
2023's Mid Cap Stocks Performance
Here are the best and worst performing companies of 2023 with the market capitalization, trading between 500 million U.S. dollars and 5 billion dollars U.S. respectively, as of 10/03/26.
2023's Small Cap Stocks Performance
The table shows the best and worst performing companies of 2023 with the market capitalization, trading between 50 million U.S. dollars and 500 million dollars U.S. respectively, as of 10/03/26.
2023's Micro Cap Stocks Performance
The list shows the best and worst performing companies of 2023 with the market capitalization, trading under 50 million U.S. dollars, as of 10/03/26.
Who are the 2023's Stock Market Losers?
KULR
-84.30%
|
|
|
Kulr Technology Group Inc
IT Infrastructure Industry
KULR
-84.30%
Kulr Technology Group Inc*s business model revolves around developing and providing thermal management solutions for electronics and energy storage applications. By leveraging their proprietary carbon fiber-based technology, they aim to enhance the safety and performance of devices in various industries. Additionally, they offer engineering services and licensing opportunities to collaborate with partners and integrate their thermal management solutions into their products.
|
ATRA
-84.36%
|
|
|
Atara Biotherapeutics Inc
Biotechnology & Pharmaceuticals Industry
ATRA
-84.36%
Atara Biotherapeutics Inc is a biotechnology company that focuses on developing therapies for patients with serious medical conditions. They utilize a personalized medicine approach to create off-the-shelf, allogeneic T-cell immunotherapies. By leveraging their expertise in T-cell immunotherapy and genetic engineering, they aim to provide innovative treatments with the potential for broad patient reach.
|
DZSI
-84.62%
|
|
|
Dzs Inc
Consumer Electronics Industry
DZSI
-84.62%
Dzs Inc is a business analytics and consulting company that provides data-driven solutions and advisory services to help organizations optimize their operations, enhance customer experiences, and drive growth. They leverage advanced technologies and domain expertise to deliver actionable insights and drive business transformation for their clients across various industries.
|
HALL
-84.76%
|
|
|
Hallmark Financial Services inc
Property & Casualty Insurance Industry
HALL
-84.76%
Hallmark Financial Services Inc operates under a business model focused on providing insurance products and services to individuals, businesses, and niche markets. Their model involves underwriting and marketing a diverse range of insurance solutions, including property and casualty, commercial, and specialty coverages. Hallmark aims to leverage its expertise in risk assessment and management to deliver tailored insurance solutions that meet the unique needs of their clients.
|
CLDI
-85.06%
|
|
|
Calidi Biotherapeutics Inc
Biotechnology & Pharmaceuticals Industry
CLDI
-85.06%
Calidi Biotherapeutics Inc*s business model revolves around developing and commercializing innovative cell-based immunotherapies for the treatment of cancer.
|
NCPL
-85.17%
|
|
|
Netcapital Inc
Miscellaneous Financial Services Industry
NCPL
-85.17%
Netcapital Inc is a financial technology platform that connects early-stage companies with potential investors. The company operates as an intermediary, facilitating the offering and sale of securities through its platform. By providing a marketplace for crowdfunding and private placements, Netcapital enables companies to raise capital and investors to access investment opportunities.
|
GNPX
-85.53%
|
|
|
Genprex Inc
Major Pharmaceutical Preparations Industry
GNPX
-85.53%
Genprex Inc*s business model focuses on the development and commercialization of gene therapies for the treatment of cancer.
|
CAPS
-85.95%
|
|
|
Capstone Holding Corp
Forestry & Wood Products Industry
CAPS
-85.95%
Capstone Therapeutics Corp.*s business model revolves around the development and commercialization of novel therapeutics for certain medical conditions. The company primarily focuses on identifying promising drug candidates, conducting preclinical and clinical studies to demonstrate their efficacy and safety, and eventually seeking regulatory approvals for commercialization. Capstone Therapeutics Corp. aims to generate revenue by partnering with pharmaceutical companies for the distribution and marketing of their developed therapeutics.
|
VERU
-85.99%
|
|
|
Veru Inc
Major Pharmaceutical Preparations Industry
VERU
-85.99%
Veru Inc operates as a pharmaceutical company primarily focused on developing and commercializing medicines for men*s and women*s health. With a combination of in-house research and partnerships, Veru Inc aims to address unmet medical needs by providing innovative therapies and products. Their business model encompasses both the development of new pharmaceuticals and the marketing and distribution of their existing products in the healthcare market.
|
LIDR
-86.10%
|
|
|
Aeye Inc
Auto & Truck Parts Industry
LIDR
-86.10%
Aeye Inc is a company that operates on a business model focused on providing advanced perception and sensor technology solutions for autonomous vehicles and intelligent machines.
|
CMAX
-86.16%
|
|
|
Caremax Inc
Healthcare Facilities Industry
CMAX
-86.16%
Caremax Inc operates as a healthcare company providing various services and products. Their business model revolves around offering a wide range of medical and healthcare solutions, including home healthcare, medical equipment, and pharmacy services. They aim to meet the diverse needs of patients, ensuring accessible and quality healthcare options through their integrated model.
|
KZR
-86.33%
|
|
|
Kezar Life Sciences Inc
Major Pharmaceutical Preparations Industry
KZR
-86.33%
Kezar Life Sciences Inc is a biotechnology company that focuses on developing novel small molecule therapeutics. Their business model revolves around the discovery and development of innovative drugs to target autoimmune and inflammatory disorders, aiming to address unmet medical needs. They primarily operate by conducting extensive research and conducting clinical trials to deliver effective treatments for patients.
|
CPHI
-86.67%
|
|
|
China Pharma Holdings Inc
Major Pharmaceutical Preparations Industry
CPHI
-86.67%
China Pharma Holdings Inc*s business model revolves around the research, development, manufacturing, and marketing of pharmaceutical products.
|
KLRS
-87.00%
|
|
|
Kalaris Therapeutics Inc
Biotechnology & Pharmaceuticals Industry
KLRS
-87.00%
The company develops and commercializes treatments for retinal diseases using the anti-VEGF drug TH103.
|
LVPA
-87.41%
|
|
|
Lvpai Group Limited
Investment Services Industry
LVPA
-87.41%
The company currently has no operations and is seeking to merge with or acquire an operating business.
|
CFOR
-87.56%
|
|
|
Capforce Inc
Medical Laboratories Industry
CFOR
-87.56%
CapForce offers capital market listing sponsorship and fintech services to growth-stage private companies.
|
|
1,882.88 %
PREV.